The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Recovery of complete antiemetic response with APF530 during treatment with moderately (MEC) and highly (HEC) emetogenic chemotherapy regimens in patients who failed palonosetron.
Roberto Arevalo-Araujo
No relevant relationships to disclose
Erin O'Boyle
Employment or Leadership Position - A.P. Pharma
Stock Ownership - A.P. Pharma
William Cooper
Employment or Leadership Position - Beardsworth Consulting Group
Paul Alexander Robertson
No relevant relationships to disclose